HIV Diagnostics Market By Product, Regional Outlook, Application Potential, Competitive Market Share & Forecast, 2018 – 2024
Global HIV Diagnostics Market is estimated to cross USD 4.9 billion by 2023; as per a new research report by Global Market Insights, Inc. Increasing prevalence of HIV infection worldwide will majorly boost HIV diagnostics market growth over the forecast period.
HIV infection is one of the leading causes of morbidity and mortality. As per the UNAIDS’s data more than 36.7 million people across the globe were living with HIV in 2017.
Around 1.8 million children aged below 15 years had HIV infection. Additionally, many were infected by their HIV-positive mothers during pregnancy, childbirth or breast-feeding.
Growing incidences of AIDS especially in the developing and underdeveloped economies will offer several growth opportunities in HIV diagnostics resulting in industry growth.
Favorable regulatory landscape for HIV diagnostics will render positive impact on business growth. The U.S. FDA assesses performance and clinical value of blood screening and HIV diagnostic assays.
It conducts regulatory study to create product standards and develop improved diagnostic methods to examine safety of biologics and drugs. FDA's multi-disciplinary research programs plays an important role in the development of test kits, vaccines, and therapeutic agents for use in AIDS and related conditions.
Hence, government support coupled with favorable reimbursement scenario for HIV diagnostics will further accelerate HIV diagnostics market growth.
Antibody tests segment dominated the HIV diagnostics market with USD 953.9 million in 2017 and is estimated to show robust growth over the forecast timeframe. Early detection ability of antibody tests including home and rapid tests in HIV infection as compared to tests with oral fluid, will boost the industry size.
Increasing awareness towards regular blood test and growing prevalence of HIV symptoms will fuel the business growth over the forecast period.
Viral identification assays segment accounted for considerable revenue share in 2017 and the segment will witness 8.4% CAGR in the coming years. Viral identification enables isolation of HIV and is used to check infection in infants born to seropositive mothers or in people with equivocal serologic studies.
Increasing initiatives to develop more improved and efficient techniques of virus identification in above mentioned infants and quantification will further accelerate industry growth.
U.S. HIV diagnostics market dominated North America and was valued at USD 876.8 million in 2017 and is estimated to witness similar trend in the coming years due to increasing prevalence of HIV infections. As per the Centers for Disease Control and Prevention (CDC’s) HIV Surveillance Report, around 1.1 million people in the U.S., aged 13 years and above were living with HIV infection at end of 2015.
High healthcare expenditure coupled with favorable regulatory landscape for HIV diagnostics will further spur the market size.
2018 Highlights of the HIV diagnostics industry penetration in low-and middle-income economies
Mylan’s collaboration agreement with Atomo Diagnostics
In 2018, Mylan N.V., the renowned generic and specialty pharmaceuticals company, made it to the headlines post its announcement of collaborative agreement with Atomo Diagnostics. The deal was announced as a strategy to make point of care rapid self-tests accessible in the low-and middle income economies wherein people can be more aware about their HIV status and seek treatment based on the results.
As a part of the deal, Mylan received rights for the commercialization of CE-Marked in-vitro diagnostic tests in more than 100 countries across Asia, the Middle East, Africa, the CIS and Latin America.
Kenya Medical Research Institute’s (KEMRI) collaboration with Roche for establishment of an advanced HIV diagnostic laboratory
In a bid to achieve the elimination of AIDS and HIV from the country by 2030, KEMRI announced ITS collaboration with Swiss pharmaceutical giant, Roche to launch an advanced HIV testing laboratory. Dubbed as Cobas 8800, the new laboratory is claimed to test approximately 1 million people yearly.
The launch is touted as one of its kind in terms of its rapidity, functionality, and accuracy. The deal also marked Kenya in the ranks of Uganda and South Africa which are the only African countries with Roche’s hi-tech HIV diagnostic laboratory.
Innovative and technologically advanced product launches chiefly characterized the HIV diagnostics industry landscape in 2018
As per WHO, new HIV infections observed a decline of 36% between 2000-2017. During the same period, HIV related deaths fell by 38%, owing to ART (antiretroviral therapy).
The numbers are undoubtedly a result of the conjoint efforts of the regulatory bodies as well as healthcare companies which are constantly developing accessible, convenient, and affordable POC tools to reach out to the HIV infected masses.
Innovative product and technology developments in the HIV diagnostics vertical that grabbed the spotlight in 2018
Abbott’s POC test for HIV Management, especially targeted toward remote communities
In a bid to provide easy and accurate management of HIV, Abbott announced the launch of its new point-of-care test, dubbed m-PIMA HIV-1/2 VL. The new technique is said to be the first for POC based viral load measurement, delivering results within 70 minutes.
The technique also supports decentralized programme management and can be used on the portable m-PIMA platform. The launch was another appreciable addition to Abbott’s rich HIV diagnostics solutions portfolio which spans across more than 120 countries worldwide, comprising all 55 African countries.
The tool is claimed to play a significant role in achieving UNAIDS’ 90-90-90 goals.
Prominent industry players operating in the HIV diagnostics market include Siemens Healthineers, Merck, PointCare Technologies, Roche Diagnostics, Sysmex Partec, Qiagen, Cepheid, Hologic, ChemBio Diagnostics, Abbott, Alere, Apogee Flow Systems, BD Biosciences, Beckman Coulter Biomedical and Biomerieux. Key industry players majorly focus on several strategic initiatives including new product launch, partnership, merger and acquisitions to strengthen their market position and capitalize on market opportunities.
For instance, in October 2016, Siemens Healthineers signed global strategic alliance of five year with IBM Watson Health in Population Health Management (PHM). This alliance helped Siemens to target hospitals, health systems and integrated delivery networks to provide value based care to patients suffering from chronic conditions.
Chapter 1. Methodology
1.2. Market definitions
1.3. Forecast parameters
1.4. Data sources
220.127.116.11. Paid sources
18.104.22.168. Unpaid sources
Chapter 2. Executive Summary
2.1. HIV diagnostics industry 3600 synopsis, 2013 - 2024
2.1.1. Business trends
2.1.2. Product trends
2.1.3. Regional trends
Chapter 3. HIV Diagnostics Industry Insights
3.1. Industry segmentation
3.2. Industry landscape, 2013 - 2024
3.3. Industry impact forces
3.3.1. Growth drivers
22.214.171.124. Favorable regulatory landscape in the U.S.
126.96.36.199. Point-of-care (POC) HIV diagnostics development
188.8.131.52. Increasing number of blood transfusions and blood donations
184.108.40.206. Rising AIDS/HIV prevalence in low and middle-income countries
220.127.116.11. Increasing government initiatives for HIV awareness
Browse Full Report at www.gminsights.com/industr…ics-market
TABLE 1 HIV diagnostics industry 360º synopsis, 2013 – 2024
TABLE 2 HIV diagnostics market, 2013-2017 (USD Million)
TABLE 3 HIV diagnostics market, 2018-2024 (USD Million)
TABLE 4 HIV diagnostics market, by product, 2013-2017 (USD Million)
TABLE 5 HIV diagnostics market, by product, 2018-2024 (USD Million)
TABLE 6 HIV diagnostics market, by region, 2013-2017 (USD Million)
TABLE 7 HIV diagnostics market, by region, 2018-2024 (USD Million)
Related Report- Healthcare Cybersecurity Market
Know more at www.marketwatch.com/press-r…2019-05-31
Category: Market Research Publishers and RetailersCompany about: Global Market Insights Inc. is a global market research and management consulting company catering to leading corporations, non-profit organizations, universities and government institutions. Our main goal is to assist and partner organizations to make lasting strategic improvements and realize growth targets. Our industry research reports are designed to provide granular quantitative information, combined with key industry insights, aimed at assisting sustainable organizational development.